Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADI study of adalimumab interval lengthening in IBD remission
NL-OMON40152Phase 3Withdrawn
- Sponsor
- Erasmus MC
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Erasmus MC. Primary endpoint: Patients in remission after 24 weeks. Planned start Feb 2014; status: withdrawn.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON40152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40152.